Zai Lab Limited (ZLAB)
$23.10-6.06%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.6B
- Beta
- 0.83
- P/E (TTM)
- -13.88
- Short % float
- 6.80%
- Days to cover
- 9.0
- SI change
- -12.3%
- 1W
- -9.70%
- 1M
- -6.02%
- vs SPY 1W
- -9.56%
- vs SPY 1M
- -8.53%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 7
- VALUE
- 9
- GROWTH
- 26
- GARP
- 7
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-16.4%
REV YoY-
ROE-27.4%
EPS YoY-
ROA-17.5%
GROSS56
OP-59
NET-42
[VALUATION]
P/E TTM-13.88
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B4.45
P/FCF-
EV/EBITDA-11.56
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E41.94
ALTMAN Z-
CURR RATIO2.13
ND/EBITDA-
BETA0.83
Company news
FAQ
- What is LOPJLB’s current signal on ZLAB?
- LOPJLB’s latest quantitative signal on Zai Lab Limited (ZLAB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ZLAB in?
- Zai Lab Limited (ZLAB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Zai Lab Limited (ZLAB) do?
- Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-mol…